PMID- 23128832
OWN - NLM
STAT- MEDLINE
DCOM- 20130506
LR  - 20181202
IS  - 1421-9751 (Electronic)
IS  - 0008-6312 (Linking)
VI  - 123
IP  - 3
DP  - 2012
TI  - Sorafenib is effective in the treatment of pulmonary veno-occlusive disease.
PG  - 172-4
LID - 10.1159/000342787 [doi]
AB  - The present study is the first report of the effectiveness of sorafenib in the 
      treatment of pulmonary veno-occlusive disease (PVOD). A 66-year-old woman with 
      PVOD was started on sorafenib. After 3 months of treatment with a maximum dosage 
      of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart 
      Association (NYHA) functional class from IV to III. However, because of severe 
      painful eruptions as a side effect of sorafenib, the patient stopped sorafenib 
      and was started on imatinib instead. This treatment resulted in a worsening of 
      the patient's NYHA class from III to IV, so sorafenib was restarted at a reduced 
      dosage of 300 mg/day. The resumption of sorafenib was associated with clinical 
      improvement, specifically NYHA class from IV to II and hemodynamic amelioration, 
      and tolerable eruptions. In conclusion, sorafenib may be a potential therapeutic 
      strategy for the treatment of PVOD.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - Kataoka, Masaharu
AU  - Kataoka M
AD  - Division of Cardiology, Department of Medicine, Kyorin University School of 
      Medicine, Tokyo, Japan.
FAU - Yanagisawa, Ryoji
AU  - Yanagisawa R
FAU - Fukuda, Keiichi
AU  - Fukuda K
FAU - Yoshino, Hideaki
AU  - Yoshino H
FAU - Satoh, Toru
AU  - Satoh T
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20121031
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Benzamides)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Aged
MH  - Benzamides/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Imatinib Mesylate
MH  - Niacinamide/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/*therapeutic use
MH  - Piperazines/therapeutic use
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pulmonary Veno-Occlusive Disease/*drug therapy
MH  - Pyrimidines/therapeutic use
MH  - Sorafenib
MH  - Treatment Outcome
EDAT- 2012/11/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2012/11/07 06:00
PHST- 2012/08/21 00:00 [received]
PHST- 2012/11/07 06:00 [entrez]
PHST- 2012/11/07 06:00 [pubmed]
PHST- 2013/05/07 06:00 [medline]
AID - 000342787 [pii]
AID - 10.1159/000342787 [doi]
PST - ppublish
SO  - Cardiology. 2012;123(3):172-4. doi: 10.1159/000342787. Epub 2012 Oct 31.